What are Teva (TEVA) restricted share units and how were they treated in this Form 4?

Each Teva restricted share unit represents a contingent right to receive one Ordinary Share or equivalent cash at settlement. In this Form 4, 14,492 restricted share units granted on June 5, 2025 vested on June 5, 2026 and were settled into 14,492 Ordinary Shares.

When were the Teva (TEVA) restricted share units granted and when did they vest for Roberto Mignone?

The restricted share units were granted to Roberto Mignone on June 5, 2025 and vested on June 5, 2026. Upon vesting, they were settled into 14,492 Ordinary Shares at a stated conversion price of $0.00 per share, eliminating that specific derivative position.

Teva (NYSE: TEVA) director exercises 14,492 RSUs, holds direct and fund shares

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Teva Pharmaceutical Industries director Roberto Mignone reported exercising restricted share units into 14,492 Ordinary Shares on June 5, 2026, at a stated price of $0.00 per share. Following this, he directly holds 119,807 Ordinary Shares.

A separate 367,600 Ordinary Shares are held of record by Swiftcurrent Master Fund Ltd., advised by Bridger Management, LLC, which Mignone manages. He may be deemed to beneficially own those shares but disclaims beneficial ownership except for his indirect pecuniary interest.

Insider Trade Summary

14,492 shares exercised/converted

Mixed 3 txns

Insider MIGNONE ROBERTO

Role null

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	14,492	$0.00	--
Exercise	Ordinary Shares	14,492	$0.00	--
holding	Ordinary Shares	--	--	--

Holdings After Transaction: Restricted Share Units — 0 shares (Direct, null); Ordinary Shares — 119,807 shares (Direct, null); Ordinary Shares — 367,600 shares (Indirect, [see footnote])

Footnotes (1)

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The 367,600 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

Key Figures

RSUs exercised: 14,492 shares Exercise price: $0.00 per share Direct holdings after transaction: 119,807 Ordinary Shares +3 more

6 metrics

RSUs exercised 14,492 shares Restricted share units settled into Ordinary Shares on June 5, 2026

Exercise price $0.00 per share Stated price for conversion of restricted share units

Direct holdings after transaction 119,807 Ordinary Shares Shares directly owned by Roberto Mignone following the Form 4 transactions

Indirect fund holdings 367,600 Ordinary Shares Shares held of record by Swiftcurrent Master Fund Ltd.

RSU grant date June 5, 2025 Date restricted share units were granted

RSU vesting date June 5, 2026 Date restricted share units vested and were settled

Key Terms

American Depositary Shares, Restricted share units, indirect pecuniary interest, Rule 16a-1(a)(1)

4 terms

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

indirect pecuniary interest financial

"Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein"

Rule 16a-1(a)(1) regulatory

"By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/08/2026 - 04:03 PM Accepted by SEC EDGAR 06/08/2026 - 04:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MIGNONE ROBERTO

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV

ISRAEL

6944020

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	06/05/2026		M		14,492	A	⁽²⁾	119,807	D
Ordinary Shares⁽¹⁾								367,600	I	[see footnote]⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽²⁾	06/05/2026		M			14,492	⁽⁴⁾	⁽⁴⁾	Ordinary Shares⁽¹⁾	14,492	$0	0	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The 367,600 Ordinary Shares disclosed in Table I of this Form 4 are held of record by Swiftcurrent Master Fund Ltd. (the "Fund"). Bridger Management, LLC is the investment adviser to the Fund and Mr. Mignone is the manager of Bridger Management, LLC. By reason of the provisions of Rule 16a-1(a)(1) under the Securities Exchange Act of 1934, as amended, Mr. Mignone may be deemed to beneficially own the Ordinary Shares held of record by the Fund. Mr. Mignone disclaims beneficial ownership of the Ordinary Shares held of record by the Fund except to the extent of his indirect pecuniary interest therein and this report shall not be deemed an admission that Mr. Mignone is the beneficial owner of the Ordinary Shares held of record by the Fund for purposes of Section 16, or for any other purpose.

4. Restricted share units were granted on June 5, 2025 and vested on June 5, 2026.

	/s/ Dov Bergwerk as attorney-in-fact for Roberto Mignone	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Teva (TEVA) report for Roberto Mignone on June 5, 2026?

Teva reported that director Roberto Mignone exercised restricted share units into 14,492 Ordinary Shares on June 5, 2026. The exercise was recorded at a price of $0.00 per share, reflecting vesting of prior equity awards rather than an open-market purchase.

How many Teva (TEVA) shares does Roberto Mignone hold directly after this Form 4 filing?

After the reported transactions, Roberto Mignone directly holds 119,807 Ordinary Shares of Teva. These shares reflect his personal direct ownership position and exclude additional Ordinary Shares held by Swiftcurrent Master Fund Ltd., which are reported separately as indirect holdings with a beneficial ownership disclaimer.

What indirect Teva (TEVA) holdings are associated with Roberto Mignone through Swiftcurrent Master Fund Ltd.?

The filing shows 367,600 Teva Ordinary Shares held of record by Swiftcurrent Master Fund Ltd. Bridger Management, LLC advises the fund, and Mignone manages Bridger. He may be deemed to beneficially own those shares but disclaims beneficial ownership except for his indirect pecuniary interest.